|
Contralateral submandibular gland dose
|
0.97 (0.95–0.98)
|
<0.0001
|
0.98 (0.95–1.00)
|
0.052
|
|
Middle pharyngeal constrictor dose
|
0.92 (0.88–0.96)
|
0.0002
|
0.95 (0.89–1.02)
|
0.18
|
|
Superior pharyngeal constrictor dose
|
0.95 (0.92–0.98)
|
0.003
|
0.98 (0.93–1.03)
|
0.38
|
|
Glottic/supraglottic larynx dose
|
0.97 (0.94–0.99)
|
0.007
|
1.02 (0.98–1.07)
|
0.40
|
|
Esophageal inlet muscles dose
|
0.98 (0.97–1.00)
|
0.03
|
0.99 (0.97–1.01)
|
0.39
|
|
Oral cavity dose
|
0.97 (0.95–0.99)
|
0.03
|
1.00 (0.97–1.04)
|
0.86
|
|
Inferior pharyngeal constrictor dose
|
0.98 (0.96–1.00)
|
0.09
| | |
|
T4 tumor stage
|
0.69 (0.42–1.15)
|
0.16
| | |
|
Parotid glands mean dose
|
0.98 (0.94–1.02)
|
0.24
| | |
|
Bilateral nodal involvement
|
0.77 (0.47–1.27)
|
0.31
| | |
|
Cricopharyngeal muscle dose
|
0.99 (0.97–1.01)
|
0.34
| | |
|
Age
|
1.00 (0.97–1.03)
|
0.96
| | |
